• 其他栏目

    马俊杰

    • 副教授 硕士生导师
    • 性别:男
    • 学历:博士研究生
    • 学位:理学博士学位
    • 入职时间:2015-07-16
    • 所在单位:华侨大学医学院
    • 电子邮箱:
    • 在职信息:在岗

    访问量:

    开通时间:..

    最后更新时间:..

    个人简介

    主要研究方向:

          针对疾病的临床需求,基于致病靶点的结构和机制,通过合理设计、合成和评价,获得兼具良好成药性和生物活性的“候选药物分子”。




    教育经历

    [1] 2012.9 -- 2015.7
    沈阳药科大学       药物化学       博士研究生       博士学位

    工作经历

    [1] 2020.1 -- 至今
    华侨大学      医学院      副教授

    [2] 2015.7 -- 2019.12
    华侨大学      医学院      讲师

    论文成果

  • [1]Design, synthesis, evaluation and molecular modeling of quinazoline derivatives bearing amino acids as small-molecule PD-L1 inhibitors.[J].Journal of Computer-Aided Molecular Design,2025,39:55.

  • [2]Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors.[J].Journal of Enzyme Inhibition and Medicinal Chemistry,2025,40(1):2461190.

  • [3]Design, Synthesis, and Evaluation of 8-(o-Tolyl)quinazoline Derivatives as Small-Molecule PD-1/PD-L1 Antagonists.ACS Medicinal Chemistry Letters,2024,15518-523.

  • [4]Advances in nonclassical phenyl bioisosteres for drug structural optimization.Future Medicinal Chemistry,2022,141681-1692.

  • [5]Advances in research on 3C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020.RSC Med. Chem.,2022,149-21.

  • [6]Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction.European Journal of Medicinal Chemistry,2022,229113998.

  • [7]Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.Future Med. Chem.,2021,1497-113.

  • [8]Design, Synthesis, Biological Activity and Molecular Docking Study of Coumarin Derivatives Bearing 2-Methyl-Biphenyl Moiety.Chem. Res. Chinese Universities,2019,35410-417.

  • [9]Semicarbazone derivatives bearing phenyl moiety: synthesis, anticancer activity, cell cycle, apoptosis-inducing and metabolic stability study.Chemical & Pharmaceutical Bulletin,2019,67351-360.